Anita D. Souza

Anita D. Souza

Auto-generated profile, based on publicly available information

Anita D. Souza

Department of Medicine, Division of Hematology and Oncology Medical College of Wisconsin Milwaukee Wisconsin USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
ADAnita D'SOuza
Anita D'SOuza
CFCaitrin Fretham
Caitrin Fretham
SLStephanie J Lee
Stephanie J Lee
MAMukta Arora
Mukta Arora
JBJanet Brunner
Janet Brunner
MHMary M Horowitz
Mary M Horowitz
Hematopoietic cell transplantation (HCT) is a well-established treatment to control and/or cure many malignant and nonmalignant diseases involving the hematopoietic system and some solid tumors. We report information about HCT procedures performed in the United States in 2018 and analyze trends and outcomes of HCT as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Overall, compared with 2017, the number of allogeneic HCTs performed in the United States increased by 1%, and the number of autologous HCTs decreased by 5%. Key findings are fewer autologous HCTs performed for non-Hodgkin lymphoma and increasing numbers of haploidentical HCTs, nearly all of which use post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis. There is a continuing increase in HCT in adults age >70 years, particularly for acute myelogenous leukemia and myelodysplastic syndromes. Survival rates by disease, disease stage, donor type, and age are presented. This report, prepared annually by the CIBMTR, provides a snapshot of current transplant activity in the United States.

1 September 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LCLuciano J. Costa
Luciano J. Costa
SCSaurabh Chhabra
Saurabh Chhabra
EMEva Medvedova
Eva Medvedova
BDBhagirathbhai Dholaria
Bhagirathbhai Dholaria
TSTimothy M. Schmidt
Timothy M. Schmidt
NCNatalie Callander
Natalie Callander
PURPOSE: The MASTER trial combined daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) in newly diagnosed multiple myeloma (NDMM), using minimal residual disease (MRD) by next-generation sequencing (NGS) to inform the use and duration of Dara-KRd post-autologous hematopoietic cell transplantation (AHCT) and treatment cessation in patients with two consecutive MRD-negative assessments. METHODS: This multicenter, single-arm, phase II trial enrolled patients with NDMM with planed enrichment for high-risk cytogenetic abnormalities (HRCAs). Patients received Dara-KRd induction, AHCT, and Dara-KRd consolidation, according to MRD status. MRD was evaluated by NGS at the end of induction, post-AHCT, and every four cycles (maximum of eight cycles) of consolidation. Primary end point was achievement of MRD negativity (< 10–5). Patients with two consecutive MRD-negative assessments entered treatment-free MRD surveillance. RESULTS: Among 123 participants, 43% had none, 37% had 1, and 20% had 2+ HRCA. Median age was 60 years (range, 36-79 years), and 96% had MRD trackable by NGS. Median follow-up was 25.1 months. Overall, 80% of patients reached MRD negativity (78%, 82%, and 79% for patients with 0, 1, and 2+ HRCA, respectively), 66% reached MRD < 10–6, and 71% reached two consecutive MRD-negative assessments during therapy, entering treatment-free surveillance. Two-year progression-free survival was 87% (91%, 97%, and 58% for patients with 0, 1, and 2+ HRCA, respectively). Cumulative incidence of MRD resurgence or progression 12 months after cessation of therapy was 4%, 0%, and 27% for patients with 0, 1, or 2+ HRCA, respectively. Most common serious adverse events were pneumonia (6%) and venous thromboembolism (3%). CONCLUSION: Dara-KRd, AHCT, and MRD response-adapted consolidation leads to high rate of MRD negativity in NDMM. For patients with 0 or 1 HRCA, this strategy creates the opportunity of MRD surveillance as an alternative to indefinite maintenance.

1 September 2017 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
ADAnita D'SOuza
Anita D'SOuza
SLStephanie Lee
Stephanie Lee
XZXiaochun Zhu
Xiaochun Zhu
MPMarcelo Pasquini
Marcelo Pasquini
Hematopoietic Cell Transplantation (HCT) is an established curative treatment for a number of malignant and nonmalignant diseases involving the hematopoietic system and some solid tumors. In this report, we provide information about the number of HCT procedures performed in the United States in 2015, and analyze trends and outcomes of HCT as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We show that the number of HCTs performed annually continues to increase, as the indications for HCT, preferred donor sources, and graft-versus-host prophylaxis continue to evolve. We report on general overall survival by indication, by disease status at transplantation, and by transplant type. This report provides a current perspective on transplantation activity in the United States with a focus on recent trends in alternative donors and contemporary transplantation practices.

27 October 2011 in Blood
Verified
Journal Article
Closed access
PDF file
ADAnita D'Souza
Anita D'Souza
SHSuzanne R. Hayman
Suzanne R. Hayman
FBFrancis Buadi
Francis Buadi
MMMichelle Mauermann
Michelle Mauermann
MLMartha Q. Lacy
Martha Q. Lacy
ADAngela Dispenzieri
Angela Dispenzieri
The POEMS syndrome is associated with elevated vascular endothelial growth factor (VEGF) levels. Several studies have compared serum VEGF levels between POEMS patients and other disease entities showing higher serum VEGF in POEMS syndrome; however, it is unknown whether serum levels are reliable and reproducible given variable platelet release of VEGF. We therefore compared plasma levels of VEGF in 29 patients with POEMS syndrome with those of other disorders (n = 76). We demonstrated that plasma VEGF levels are useful in differentiating POEMS from other plasma cell dyscrasias, neuropathic processes, and multisystem illnesses. Plasma VEGF is also useful in monitoring disease activity after treatment and correlates with clinical improvements better than hematologic response.

10 November 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ADAnita D'Souza
Anita D'Souza
ADAngela Dispenzieri
Angela Dispenzieri
BWBaldeep Wirk
Baldeep Wirk
MZMei-Jie Zhang
Mei-Jie Zhang
JHJiaxing Huang
Jiaxing Huang
PHParameswaran Hari
Parameswaran Hari
Purpose: Autologous hematopoietic cell transplantation, or autotransplantation, is effective in light-chain amyloidosis (AL), but it is associated with a high risk of early mortality (EM). In a multicenter randomized comparison against oral chemotherapy, autotransplantation was associated with 24% EM. We analyzed trends in outcomes after autologous hematopoietic cell transplantation for AL in North America. Patients and Methods: Between 1995 and 2012, 1,536 patients with AL who underwent autotransplantation at 134 centers were identified in the Center for International Blood and Marrow Transplant Research database. EM and overall survival (OS) were analyzed in three time cohorts: 1995 to 2000 (n = 140), 2001 to 2006 (n = 596), and 2007 to 2012 (n = 800). Hematologic and renal responses and factors associated with EM, relapse and/or progression, progression-free survival and OS were analyzed in more recent subgroups from 2001 to 2006 (n = 197) and from 2007 to 2012 (n = 157). Results: Mortality at 30 and 100 days progressively declined over successive time periods from 11% and 20%, respectively, in 1995 to 2000 to 5% and 11%, respectively, in 2001 to 2006, and to 3% and 5%, respectively, in 2007 to 2012. Correspondingly, 5-year OS improved from 55% in 1995 to 2000 to 61% in 2001 to 2006 and to 77% in 2007 to 2012. Hematologic response to transplantation improved in the latest cohort. Renal response rate was 32%. Centers performing more than four AL transplantations per year had superior survival outcomes. In the multivariable analysis, cardiac AL was associated with high EM and inferior progression-free survival and OS. Autotransplantation in 2007 to 2012 and use of higher dosages of melphalan were associated with a lowered relapse risk. A Karnofsky score less than 80 and creatinine levels 2 mg/m2 or greater were associated with worsened OS. Conclusion: Post-transplantation survival in AL has improved, with a dramatic reduction in early post-transplantation mortality and excellent 5-year survival. The risk-benefit ratio for autotransplantation has changed, and randomized comparison with nontransplantation approaches is again warranted.

1 March 2018 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
BDBinod Dhakal
Binod Dhakal
ASAniko Szabo
Aniko Szabo
SCSaurabh Chhabra
Saurabh Chhabra
MHMehdi Hamadani
Mehdi Hamadani
ADAnita D’souza
Anita D’souza
PHParameswaran N. Hari
Parameswaran N. Hari
High-dose therapy with melphalan followed by autologous stem cell transplant—a combination henceforth referred to as HDT/ASCT—has been the standard treatment for newly diagnosed patients with multiple myeloma (MM) for the past 20 years. Several phase 3 studies conducted before the advent of modern induction therapy with immunomodulatory drugs and proteasome inhibitors (also called “novel agents”)1-4 confirmed that HDT/ASCT was associated with improved response rates (RR), progression-free survival (PFS), and even overall survival (OS) in some studies.2,4 Given the unprecedented efficacy of novel agents, investigators have sought to reevaluate the role of HDT/ASCT. All prospective studies performed in the recent era have consistently shown a PFS benefit,5-8 but their effect on RR and OS compared with the standard-dose therapy (SDT) has been variable.5,6 Some of these discrepancies have been attributed to the use of suboptimal induction regimens, single HDT/ASCT (HDT1) vs tandem HDT/ASCT (HDT2) in the study arm, and inadequate follow-up across studies. The role of HDT2 compared withHDT1 remains unclear, especially after recent results of 2 large randomized trials that had divergent results.9,10 Furthermore, 2 studies7,8 that compared HDT2 with SDT showed OS benefit, but the study that compared HDT1 with SDT did not.5 There are no randomized trials directly comparing HDT1 vs HDT2 and SDT in patients with newly diagnosed MM. Moreover, indirect comparisons of these approaches are not available as well. There is a need to clarify the relative benefits of HDT1 or HDT2 and posttransplant consolidation in the context of modern novel agent induction therapy.